-
Posted by
Two Blokes Jul 10 -
Filed in
Stock
-
9 views
PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care today announced updated results from its ongoing Phase 2 study of Bria-IMT\u2122 in combination with check point inhibitor in patients with advanced metastatic breast cancer (MBC).
